SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY™ BP Stent Clinical Overview

The SYNERGY™ Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Explore

 

Heal With Confidence: Leading in Complex Patients

  

Consistently Low ST Rates

Kang Network Meta-Analysis
SCAAR Registry
 

Leading On Studying Short DAPT

 
 

ARC definite/probable ST
vs. performance goal4

0.2% ST Rate

ARC definite/probable ST vs. performance goal chart

Adjusted death/MI with 3-month DAPT
vs. historical control

Non-Inferior

Adjusted death/MI with 3-month DAPT vs. historical control chart
 
 

All patients

All patients chart

1-month DAPT discontinuation cohort§§ 

1-month DAPT discontinuation cohort
 
POEM Trial: 1-year results
  

Excellent Outcomes in Long Lesions

  • 100 patients
  • 15 sites across US, Europe, and New Zealand
  • 100% B2/C lesions
  • 27% diabetes mellitus
 
 
 
 
 
 

Excellent Outcomes in STEMI Patients

 
 
 
 
 

Xtra Deliverability

Xtra Deliverability

Learn about the continued advancement in deliverability that SYNERGY™ XD offers

Button
SYNERGY™ XD 48 mm

SYNERGY™ XD 48 mm

Discover the First 48mm DES approved by US FDA

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing

Button

Request a rep

Fill out a quick form and one of our sales representatives will be in touch.

Top